VIRMA enhanced the stability of RAB27B mRNA through m6A/YTHDF1, upregulating its expression and promoting CML cell proliferation, thereby inducing imatinib resistance [42]. Here, VIRMA is linked to chronic myelogenous leukemia, BCR-ABL1 positive.